Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer Inc. continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology Congress ...

As of March 31, 2025, Pfizer had cash and cash equivalents of $17.3 billion on its balance sheet and $57.6 billion in long-term debt. Its debt-to-capital ratio of 0.41 is slightly higher than the ...

Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion; Proposed combination enhances Pfizer’s position as a leading company in ...

Demand for Pfizer’s COVID-19 products and oncology drugs could fall short of expectations, and risks related to key product sales, pricing pressure, and pipeline developments persist.